Canagliflozin reduced the risk of the primary composite outcome (ESKD, doubling of serum creatinine, or renal or cardiovascular death) by 30% compared to placebo, with consistent effects across all prespecified subgroups [46]
Glucagon-like peptide-1 (GLP-1) receptor agonistsincluding semaglutide (Ozempic, Wegovy), liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), and tirzepatide (Mounjaro, Zepbound)are FDA-approved medications for type 2 diabetes and chronic weight management
The most persistent misconception: I lost the weight, so I can stop. Discontinuation typically leads to regain of roughly two-thirds of lost weight over time
Within a couple of months she had lost almost 20 pounds, and that felt great
10.1056/NEJMoa1603827
The AMDR for protein was established to align with the protein intake necessary to meet the minimum RDA of 0.8 g/kg/d, with the upper limit reflecting the mathematical difference of the respective AMDR for carbohydrates and fat (42)
